Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
April 15, 2004
Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors
Andrew J Peat, Joyce A Boucheron, Scott H Dickerson, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues
Steven M Sparks, Pierette Banker, David M Bickett, et al.
Nature Communications
|
May 8, 2019
The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription
Navdeep Malik, Hualong Yan, Nellie Moshkovich, et al.
British Journal of Pharmacology
|
May 17, 2006
Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules
Celia P Briscoe, Andrew J Peat, Stephen C McKeown, et al.
Antimicrobial Agents and Chemotherapy
|
August 12, 2015
Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein
Jeffrey J Pouliot, Michael Thomson, Mi Xie, et al.
EMBO Reports
|
May 5, 2021
Fatty acid oxidation is required for embryonic stem cell survival during metabolic stress
Hualong Yan, Navdeep Malik, Young-Im Kim, et al.
Journal of Medicinal Chemistry
|
February 15, 2019
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor
Pek Y Chong, J Brad Shotwell, John Miller, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups
Steven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy
Stephen A Thomson, Pierette Banker, D Mark Bickett, et al.
Molecular Cancer Therapeutics
|
August 5, 2020
Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
Joy M Gary, John K Simmons, Jinfei Xu, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
Bioorganic & Medicinal Chemistry Letters
|
April 15, 2004
Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors
Andrew J Peat, Joyce A Boucheron, Scott H Dickerson, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues
Steven M Sparks, Pierette Banker, David M Bickett, et al.
Nature Communications
|
May 8, 2019
The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription
Navdeep Malik, Hualong Yan, Nellie Moshkovich, et al.
British Journal of Pharmacology
|
May 17, 2006
Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules
Celia P Briscoe, Andrew J Peat, Stephen C McKeown, et al.
Antimicrobial Agents and Chemotherapy
|
August 12, 2015
Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein
Jeffrey J Pouliot, Michael Thomson, Mi Xie, et al.
EMBO Reports
|
May 5, 2021
Fatty acid oxidation is required for embryonic stem cell survival during metabolic stress
Hualong Yan, Navdeep Malik, Young-Im Kim, et al.
Journal of Medicinal Chemistry
|
February 15, 2019
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor
Pek Y Chong, J Brad Shotwell, John Miller, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups
Steven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy
Stephen A Thomson, Pierette Banker, D Mark Bickett, et al.
Molecular Cancer Therapeutics
|
August 5, 2020
Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
Joy M Gary, John K Simmons, Jinfei Xu, et al.
Page
of 8